Answers are grounded in this paper and cite their sources.
Cohort study shows high survival outcomes in advanced non-small cell lung cancer with pembrolizumab, suggesting effectiveness.
This cohort study found that, among long-term cancer survivors with advanced non-small cell lung cancer who were treated with pembrolizumab, survival outcomes were high and immunotherapy rechallenge was uncommon.
No takes yet. Share an insight, caveat, or question.
Rousseau et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: